Metagenomi, Inc. IPO Advisory
Share this IPO Profile:Smart Search
For IPO Boutique's "scale of 1 to 5" BUY rating on Metagenomi, Inc., and our comprehensive analysis, click "Buy Market Research".
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Metagenomi, Inc. | MGX - NASDAQ |
$15.00-$17.00 | $15.00 | $10.25 | 6.25 million | 2/9/2024 |
| J.P. Morgan, Jefferies, TD Cowen, Wells Fargo Securities, BMO Capital Markets | ||||||
Co-Manager(s): Chardan | ||||||
| Health Care | ||||||
Filing(s): Filed 2024-01-05 Terms Added 2024-02-05 | ||||||
Metagenomi, Inc. Quote & Chart - Click for current quote - MGX
IPO Boutique aggregates information on public companies and private companies, such as "MGX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Metagenomi, Inc. (adapted from Metagenomi, Inc. prospectus):
They are a precision genetic medicines company committed to developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a precision genetic medicines company committed to developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "MGX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.